resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TORC
CUSIPN/A
Phone857-315-5521
Debt
Debt-to-Equity RatioN/A
Current Ratio11.08
Quick Ratio11.08
Price-To-Earnings
Trailing P/E Ratio-1.19
Forward P/E Ratio-5.75
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($1.17) per share
Price / Book-8.60
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees7
Outstanding Shares28,050,000
Market Cap$317.48 million
resTORbio (NASDAQ:TORC) Frequently Asked Questions
What is resTORbio's stock symbol?
resTORbio trades on the NASDAQ under the ticker symbol "TORC."
How were resTORbio's earnings last quarter?
resTORbio, Inc. (NASDAQ:TORC) announced its quarterly earnings results on Thursday, August, 9th. The company reported ($0.48) EPS for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.06. View resTORbio's Earnings History.
When is resTORbio's next earnings date?
What price target have analysts set for TORC?
4 analysts have issued 12-month price targets for resTORbio's shares. Their predictions range from $23.00 to $36.00. On average, they anticipate resTORbio's share price to reach $29.25 in the next year. This suggests a possible upside of 190.8% from the stock's current price. View Analyst Price Targets for resTORbio.
What is the consensus analysts' recommendation for resTORbio?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for resTORbio in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for resTORbio.
Are investors shorting resTORbio?
resTORbio saw a increase in short interest in July. As of July 13th, there was short interest totalling 2,326,200 shares, an increase of 34.3% from the June 29th total of 1,731,553 shares. Based on an average daily volume of 293,652 shares, the days-to-cover ratio is currently 7.9 days. Approximately 18.7% of the company's shares are sold short. View resTORbio's Current Options Chain.
Who are some of resTORbio's key competitors?
Some companies that are related to resTORbio include Esperion Therapeutics (ESPR), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Athenex (ATNX), Lexicon Pharmaceuticals (LXRX), Intra-Cellular Therapies (ITCI), Vanda Pharmaceuticals (VNDA), Endocyte (ECYT), Zai Lab (ZLAB), Karyopharm Therapeutics (KPTI), CytomX Therapeutics (CTMX), Rhythm Pharmaceuticals (RYTM), Retrophin (RTRX), Apellis Pharmaceuticals (APLS) and Radius Health (RDUS).
Who are resTORbio's key executives?
resTORbio's management team includes the folowing people:
- Mr. Chen Schor, Co-Founder, Pres, CEO & Director (Age 46)
- Dr. Joan Mannick M.D., Co-Founder & Chief Medical Officer (Age 59)
- Mr. John J. McCabe CPA, CPA, VP of Fin. (Age 50)
- Dr. Abdellah Sentissi Ph.D., Head of CMC & Pharmaceutical Devel. (Age 68)
- Ms. Susan Stewart J.D., Head of Regulatory Affairs
When did resTORbio IPO?
(TORC) raised $86 million in an initial public offering on Friday, January 26th 2018. The company issued 5,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
When did resTORbio's lock-up period expire?
resTORbio's lock-up period expired on Wednesday, July 25th. resTORbio had issued 5,666,667 shares in its public offering on January 26th. The total size of the offering was $85,000,005 based on an initial share price of $15.00. Since the expiration of resTORbio's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.
Has resTORbio been receiving favorable news coverage?
News coverage about TORC stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. resTORbio earned a media and rumor sentiment score of 0.22 on Accern's scale. They also assigned news articles about the company an impact score of 47.87 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for resTORbio.
Who are resTORbio's major shareholders?
resTORbio's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (7.21%), Jennison Associates LLC (3.93%), Baillie Gifford & Co. (3.17%), Segantii Capital Management Ltd (1.17%), BlackRock Inc. (1.14%) and Deltec Asset Management LLC (0.98%). Company insiders that own resTORbio stock include Chen Schor, Orbimed Advisors Llc and Puretech Health Llc. View Institutional Ownership Trends for resTORbio.
Which institutional investors are selling resTORbio stock?
Which institutional investors are buying resTORbio stock?
TORC stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Jennison Associates LLC, Deltec Asset Management LLC, Segantii Capital Management Ltd, SCP Investment LP, Alps Advisors Inc., Bank Hapoalim BM and Wedbush Securities Inc.. Company insiders that have bought resTORbio stock in the last two years include Chen Schor, Orbimed Advisors Llc and Puretech Health Llc. View Insider Buying and Selling for resTORbio.
How do I buy shares of resTORbio?
Shares of TORC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is resTORbio's stock price today?
One share of TORC stock can currently be purchased for approximately $10.06.
How big of a company is resTORbio?
resTORbio has a market capitalization of $317.48 million. The company earns $-33,770,000.00 in net income (profit) each year or ($8.42) on an earnings per share basis. resTORbio employs 7 workers across the globe.
How can I contact resTORbio?
resTORbio's mailing address is 500 BOYLSTON STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-315-5521.
MarketBeat Community Rating for resTORbio (NASDAQ TORC)
MarketBeat's community ratings are surveys of what our community members think about resTORbio and other stocks. Vote "Outperform" if you believe TORC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TORC will underperform the S&P 500 over the long term. You may vote once every thirty days.
